Loading...
•
Dec 31, 2024
LeMaitre Vascular Q4 2024 Earnings Report
LeMaitre Vascular reported strong Q4 2024 financial results with significant growth in sales, operating income, and EPS.
Key Takeaways
LeMaitre Vascular reported a productive Q4 2024 with sales up 14%, operating income up 26%, and EPS up 30%. The company also announced an increased quarterly dividend and authorized a share repurchase program.
Sales increased 14% to $55.7 million in Q4 2024, driven by strong organic growth.
Operating income grew 26% to $12.9 million, with an operating margin of 23%.
Diluted earnings per share rose 30% to $0.49.
The company's cash balance increased sequentially to $299.7 million, providing strategic optionality.
Revenue by Geographic Location
Forward Guidance
LeMaitre Vascular provided Q1 2025 and Full Year 2025 guidance, projecting continued growth in sales, operating income, and EPS.
Positive Outlook
- Q1 2025 sales guidance of $56.7mm - $58.7mm, representing 8%-10% organic growth.
- Full Year 2025 sales guidance of $235.4mm - $242.8mm, representing 9%-10% organic growth.
- Projected Q1 2025 operating income of $12.3mm - $13.7mm, with a 23% operating margin.
- Projected Full Year 2025 operating income of $57.3mm - $62.4mm, with a 25% operating margin.
- Projected Q1 2025 EPS of $0.48 - $0.53, representing 15% growth.
Challenges Ahead
- No specific negative guidance points were highlighted in the provided text.
- Potential impact of currency exchange rate fluctuations on adjusted net sales.
- Competition from other medical device companies and alternative medical technologies.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...